Orphan Therapeutics Accelerator Launches Orphan Therapies, a Non-Profit Biotech Dedicated to Commercializing Ultra-Rare Disease Treatments
Orphan Therapies will provide a pathway for patients to access ultra-rare disease treatments that otherwise would not be commercialized
CAMBRIDGE, Mass. – August 12, 2025 – Orphan Therapeutics Accelerator (OTXL), a non-profit organization focused on advancing shelved ultra-rare disease treatments through clinical trials, today announced the launch of its wholly owned subsidiary, Orphan Therapies (OT) LLC. Orphan Therapies will focus on commercializing and providing sustained, equitable patient access to approved therapies for conditions with very small patient populations.
Orphan Therapies will manage commercial access, distribution, and patient services for approved treatments, ensuring that potentially life-changing medicines reach the patients who need them. Many of these therapies have been abandoned by traditional biotech due to business model challenges associated with addressable market sizes that can be below a few hundred identified patients, or even less, globally.
The new subsidiary’s non-profit model is specifically designed to address this commercialization gap in ultra-rare diseases. OT will help sustain and scale patient access to treatments by operating without the high-pressure demands for profitability that often prevent treatments for the smallest patient populations from reaching the market.
“Our goal in establishing OTXL was to rescue and advance promising therapies that were abandoned in clinical trials, complete development, and get them approved,” said Craig Martin, CEO of Orphan Therapeutics Accelerator. “We’ve seen, however, that the cost of commercializing therapies for very small numbers of patients is often prohibitive in a for-profit business model. Orphan Therapies enables us to ensure sustained commercial access to approved treatments that we or others develop but that can’t meet most for-profit companies’ revenue thresholds.”
Recent market and policy shifts have made the path to commercialization even more difficult for advanced gene and cell therapies targeting ultra-rare diseases. By consolidating development expertise within OTXL and creating a specialized, non-profit commercial arm in OT, the organization offers a comprehensive solution. OT’s streamlined commercialization model is intended to generate sufficient revenue to support its own operations while channeling excess income back to OTXL to fund development efforts for additional patient treatments.
“We are building a dedicated team of experienced professionals and partners in patient services, market access, and medical affairs within Orphan Therapies,” added Beth White, COO of Orphan Therapeutics Accelerator. “Our unique structure allows us to partner closely with organizations, including academic medical centers and international organizations, that may lack the expertise or infrastructure for complex U.S. distribution. We are leveraging decades of industry experience to commercialize efficiently, focusing every dollar on the mission of patient delivery and accessibility.”
Orphan Therapies expects to announce its first therapy candidate for commercialization by the end of 2025.
###
About Orphan Therapies (OT)
Orphan Therapies is a wholly owned subsidiary of the Orphan Therapeutics Accelerator (OTXL), a non-profit focused on advancing shelved ultra-rare disease treatments through clinical trials. Orphan Therapies provides commercial access to approved treatments for very rare conditions where high costs and small patient populations make commercialization by traditional biotech companies unviable. Its streamlined, non-profit model enables operation with a primary focus on sustaining and scaling access to treatments, while generating revenues that support OTXL’s ongoing mission to deliver more treatments to patients.